Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
148.42
-6.54 (-4.22%)
4:51:05 PM EDT: $148.87 +0.45 (+0.30%)
Products

Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Published: 12/10/2021 12:12 GMT
Moderna Inc (MRNA) - Moderna Announces Positive Interim Phase 1 Data for Mrna Flu Vaccine and Provides Program Update.
Moderna Inc - Phase 2 Dose-confirmation Study Was Fully Enrolled in November (n=500); Preparation for Phase 3 Study Underway.
Moderna Inc - Seasonal Flu Program Now Moving Beyond Quadrivalent: Announcing Mrna-1011 & Mrna-1012 Development Candidates.
Moderna Inc - Phase 1 Study of Quadrivalent Flu Vaccine (mrna-1010) Successfully Boosted Titers Against All Four Strains in Older and Younger Adults.
Moderna Inc - No Significant Safety Concerns Were Observed.
Moderna Inc - Preparation for Phase 3 Study for Mrna-1010 is Already Underway, Including Manufacturing.
Moderna Inc - Company is Seeking Guidance From Global Regulatory Agencies on Phase 3 Program.
Moderna Inc - Phase 2 Study Was Fully Enrolled in November (n=500), and Interim Analysis is Expected in Early 2022.
Moderna Inc - Announced Two Beyond Quadrivalent Development Candidates Which Company Believes Offer Opportunity to Expand Strain Coverage.
Moderna Inc - Mrna-1011 Will Have One Additional Hemagglutinin (ha) Antigen and Mrna-1012 Will Have Two Additional Ha Antigens.